Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Otsuka loses lawsuit challenging FDA approval of generic Abilify

Otsuka Pharmaceutical Co Ltd has lost a lawsuit challenging the U.S. Food and Drug Administration’s decision to allow generic versions of the company’s antipsychotic drug Abilify. At the end of April, the FDA approved applications to make Abilify by several generic drugmakers, including Teva Pharmaceutical Industries Ltd, which immediately announced it would launch its own […]

Read More »

Amarin’s Lawsuit Could Have Huge Benefits For Pharma Industry And Dire Consequences For Consumers

Pharma companies have long demonstrated that they will employ questionable marketing and sales tactics to boost sales, no matter what the impact is on patients’ health. Now Amarin, a small drug maker that sells the prescription drug Vascepa, hopes to bolster its bottom line by suing the Food and Drug Administration, claiming that the company’s […]

Read More »

Amarin Granted Summary Judgment Motion in Suit Against FDA Seeking New Chemical Entity Market Exclusivity for Vascepa(R) (Icosapent Ethyl) Capsules

BEDMINSTER, NJ and DUBLIN, IRELAND–(Marketwired – May 28, 2015) – Amarin Corporation plc (NASDAQ: AMRN), announced today that Judge Randolph D. Moss of the federal district court for the District of Columbia has granted Amarin’s motion for summary judgment in the company’s lawsuit against the United States Food and Drug Administration (FDA) seeking an order […]

Read More »

New drugs from Bristol, Merck at forefront of cancer meeting

New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body’s immune system to fight cancer can be used. Results from key clinical trials will be presented starting Friday in Chicago at the annual meeting of the American Society of Clinical Oncology. These will include […]

Read More »

Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults

DUBLIN, May 27, 2015 /PRNewswire/ — Actavis plc (NYSE: ACT) announced today that VIBERZI™ (eluxadoline) was approved by the Food and Drug Administration (FDA) as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, […]

Read More »

FDA approves Actavis, Valeant drugs for irritable bowel syndrome

U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc and Valeant Pharmaceuticals International Inc on Wednesday, validating big investments both companies made to acquire the products. The Food and Drug Administration approved eluxadoline, to be sold under the brand name Viberzi, which Actavis obtained with its $1.1 billion acquisition last year of […]

Read More »

Vanda Receives Innovation Award from the National Organization for Rare Disorders for Development of HETLIOZ

WASHINGTON, May 26, 2015 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has received the 2015 Industry Innovation Award from the National Organization of Rare Disorders (NORD) in recognition of Vanda’s work in developing HETLIOZ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).  This award was presented to Vanda at the […]

Read More »

Research and Markets: Global Hemophilia Market Report: 2015 Edition: Market is Intense Among Large Players like with Baxter International, Novo Nordisk and Pfizer

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/j63nc2/global_hemophilia) has announced the addition of the “Global Hemophilia Market Report: 2015 Edition” report to their offering. Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia […]

Read More »

Does Botox Actually Rejuvenate Your Skin? University of Ottawa Study

Pliability, Elasticity Of Skin Increase Following Wrinkle Treatment With Botox Skin pliability and elasticity improved after treatment with onabotulinum toxin (Botox) for mild facial wrinkles and the effect lasted for up to four months, according to a report published online by JAMA Facial Plastic Surgery. Human skin has three biomechanical features: strength, pliability (the ability […]

Read More »

European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom’s Macroglobulinemia

SUNNYVALE, Calif., May 22, 2015 /PRNewswire/ — Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending a change to the terms of the marketing authorization for IMBRUVICA® (ibrutinib) in the European Union to indicate the treatment of adult […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom